Amgen's Repatha cholesterol drug significantly reduces the risk of first cardiac events by 25% in at-risk patients.

On Oct. 10, the FDA classified the recalled prescription medication as a Class II recall. The risk classification from the federal agency indicates that the recalled medications could cause "temporary ...

A new once-a-day pill, Enlicitide, has shown to lower “bad” LDL cholesterol by up to 60% in clinical trials, offering hope ...

A growing body of research has shown that the food choices we make daily play a crucial role in keeping our hearts healthy. Studies by the American College of Cardiology and the Journal of the ...

A novel once-daily oral PCSK9 inhibitor lowered LDL by up to 60% at 24 weeks in patients with heart disease or at high risk ...

Guidelines disagree on whether children should be screened to identify familial hypercholesterolemia, which is associated ...

In the United States, 1 in every 250 people has inherited a genetic variant that leads to dangerously high cholesterol levels ...

A CRISPR-based gene therapy showed improvement in lipids in difficult-to-treat patients, but one study raised flags after a ...

Researchers from Mass General Brigham have unveiled the results of a large clinical trial that found that adding the drug ...

With a snip of a gene, doctors may one day permanently lower dangerously high cholesterol, possibly removing the need for ...

More than 140,000 bottles of a popular drug commonly prescribed to reduce cholesterol have been recalled for a defect that could make the medication less effective.

Several lots of the cholesterol medication atorvastatin were recalled after failed dissolution tests, according to the FDA.